Development of Seraseq FFPE Homologous Recombination Deficiency Reference Materials for NGS Assay Validation
Homologous recombination deficiency (HRD) arises due to a defect in DNA repair and serves as an important therapeutic biomarker. NGS assays that measure HRD status via genomic instability are used to stratify ovarian and breast cancer patients and determine eligibility for clinical trials, and PARP inhibitor- and platinum-based therapies. Testing is performed on FFPE biopsied tissue, and despite the challenges of this sample type and complexity of analysis, there are currently no commercially available HRD reference materials that enable standardization between assays. Therefore, such reference materials were developed to aid in developing and validating NGS-based HRD assays and for quality control monitoring of genomic instability scores (GIS).
To download, fill out the form and you will receive an email with the content.